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Hepatocellular carcinoma (HCC) remains a leading cause of cancer death worldwide,
and despite recent immunotherapeutic advances there remains a need for improved
diagnostic, prognostic, and therapeutic tools. UL-16 binding protein 1 (ULBP1) is a ligand
of the activatory receptor Natural Killer cell Group 2 receptor D (NKG2D) and is found
as a cell-surface protein on some malignant cells including on human hepatocellular
carcinomas. We aimed to explore the biological and clinical significance of NKG2D
ligands in the circulation of patients with HCC. We measured ULBP1 in the serum
of two retrospective cohorts of patients with HCC from the PROLIFICA cohort in The
Gambia (n = 43) and from a tertiary care setting in the UK (n = 72) by sandwich
ELISA. Exosome isolation by size exclusion was used to compare ULBP1 concentration
in exosomes and as free protein. Survival analysis was performed and multiple linear
regression and Poisson regression were used to assess the independent effect of
ULBP1 concentration. ULBP1 was raised in both cohorts with HCC regardless of the
underlying liver disease, and was not associated with markers of cirrhosis such as platelet
count or serum albumin. ULBP1 was present predominantly as free protein rather than
bound to exosomes. Serum ULBP1 > 2000 pg/ml was associated with a significantly
reduced survival in both cohorts (hazard ratios in Gambian and UK cohorts 2.37 and
2.1, respectively). The effect remained significant after adjustment for BCLC staging
(p = 0.03). These data suggest that ULBP1 merits further investigation as a prognostic
marker in HCC in diverse settings and should also be explored as a therapeutic target.
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INTRODUCTION
Hepatocellular carcinoma (HCC) is the third leading cause of cancer death worldwide
(1), and prognosis remains poor even in rich countries, with limited treatment options
(2). Worldwide, hepatitis B virus (HBV) is the most common underlying etiological
agent (3), with hepatitis C and other liver diseases accounting for the remainder.
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HCC is relatively resistant to chemo- and radiotherapy, and
although early-stage tumors can be cured by surgical resection
or liver transplant, with radio-frequency ablation possible in
a proportion of small tumors, most cases present late when
treatment options are limited (2). The tyrosine kinase inhibitor
Sorafenib prolongs survival but is not curative (4) and more
recently PD-1 blockade with Nivolumab has been shown
to induce objective response in a minority of patients (5).
Despite this recent progress, novel treatment modalities are
needed and immunotherapeutics involving NKG2D are one
possible approach.
The NKG2D ligands ULBP1-6, MICA, and MICB are
expressed by cells undergoing viral infection, malignant
transformation and cellular stresses (6). They engage NKG2D,
an activatory receptor expressed by NK cells and CD8T cells,
stimulating cytotoxicity (7). NKG2D has an important role in
immune surveillance (8) and malignant tumors may release
soluble NKG2D ligands as an immune evasion strategy to evade
detection by NK and T cells and impair NKG2D function (9, 10).
NKG2D ligands may be released by proteolytic shedding or
on exosomes (11, 12). Soluble NKG2D ligands are generally
thought to act by NKG2D downregulation, impairing the ability
of NK and cytotoxic T cells to respond to target cells (9).
However, in some murine systems soluble NKG2D ligands act
differently, blocking a tonic NKG2D downregulation due to
ligands expressed on the surface of parenchymal cells, resulting
in improved NK cell killing (13).
The NKG2D pathway has received increasing attention over
recent years as a potential therapeutic target in cancer (14, 15).
Novel agents designed to target NK cells to NKG2D ligand-
expressing tumor cells are under investigation, predominantly
in the setting of hematological malignancy (16, 17). Recently
antibodies against the α3 domain of MICA, simultaneously
blocking the site of proteolytic cleavage and providing a second
activatory signal to NK cells via the Fc-gamma receptor CD16,
have been shown to be therapeutic in a mouse model of human
melanoma (18), demonstrating that such approaches could be
beneficial in solid-organ malignancy.
Liver tissue andHCC contain large numbers of NK and CD8T
cells. Immunohistochemical studies of HCC have demonstrated
lymphocytic infiltrates with CD8T cells predominating over CD4
cells (19, 20). More detailed characterization of lymphocytes in
multiple studies of human liver has demonstrated populations
of NK cells, T cells and NKT cells and more recently work
from our group and others has demonstrated a population
of liver-resident NK cells not represented in peripheral blood,
and shown the presence of NK cells infiltrating HCC and
demonstrating marked functional impairment (21–23). Single
cell RNA-seq of cells isolated from HCC demonstrates multiple
NK cell clusters and T cells exhibiting an exhausted phenotype
(24, 25). Immunohistochemistry of tumor has shown NKG2D
ligand loss at the cell surface associated with more poorly
differentiated HCC and reduced disease-free survival (26). Given
the limited treatment options in HCC and the availability
of potential tools to recruit effector cells at the site of, and
infiltrating the tumor, we therefore sought to explore whether
NKG2D-ligands were shed into serum in patients with HCC,




ELISAs for MICA, MICB, ULBP1, ULBP2, and ULBP3 (R&D)
were performed as per the manufacturer’s instructions. All
samples and standards were assayed in duplicate. Plates were
read immediately using an automated plate reader (Finstruments
Multiskan) at 450 nm. Mean optical densities (OD) for each
standard and sample were taken and antigen concentrations were
calculated using Excel for Mac 2011 (Microsoft).
Exosome Isolation and Imaging Cytometry
Exosomes were isolated from serum using Izon Science
qEV Size Exclusion Columns according to the manufacturer’s
instructions. For identification of exosomes in serum, Fc
receptor blocking reagent (Miltenyi) was added to paired serum,
exosome and protein fractions before staining with BODIPY-
FL (ThermoFisher) and ULBP1-PE (R&D). Samples were fixed
with Cytofix (BD) before acquisition. Samples were acquired
by ImagestreamXL (Amnis) and data analysis performed using
IDEAS software (Amnis).
PBMC Isolation
PBMC were isolated by density gradient centrifugation using
Ficoll-Hypaque (GE Healthcare). Peripheral blood was collected
into vacutainers containing EDTA (BD). Using 15ml falcon tubes
(Sarstedt), 10ml blood was carefully layered onto 5ml Ficoll-
Hypaque and centrifuged at 2,000 rpm, acceleration 6, brake 4 in
a Thermo Multifuge centrifuge. The PBMC layer was removed
using a Pasteur pipette and washed in Roswell Park Memorial
Institute (RPMI) medium (Gibco). Cells were either stained
immediately for flow cytometry or counted using trypan blue
(Sigma) and transferred to freezing medium (FBS (Sigma) with
10% dimethylsulfoxide (DMSO) (Sigma) at a concentration of
10 million cells/ml for cryopreservation, initially at−80◦C before
transfer to liquid nitrogen for long-term storage. Before use cells
were thawed in a water bath at 37◦C and washed in 20 ml RPMI.
Flow Cytometry
All samples were treated with Fc receptor blocking reagent
(Miltenyi Biotec) before staining. Surface staining was performed
in 96 well plates (Sarstedt) in staining buffer of 50% PBS,
50% Brilliant Violet staining buffer (BD). Fixable live/dead stain
(Life Technologies) was added to the staining buffer. Antibody
staining was conducted for 15min at 37◦C in the dark before
washing with PBS using the following monoclonal antibodies:
CD3 PE-Cy7 and CD8 Alexa 700 (eBioscience), CD56 ECD
(Beckman Coulter), NKG2DAlexa 488 (Biolegend). Cell viability
was determined and dead cells excluded using fixable live/dead
aqua stain (Invitrogen). Samples for were fixed in Cytofix
(BD). Single fluorochrome compensation controls were made
using compensation beads (BD). Compensation matrices were
calculated initially in FACSDiva and edited where necessary in
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FlowJo X (TreeStar). Samples were acquired on LSR Fortessa
(BD) and data analyzed in FlowJo X.
Clinical Groups
Participants were recruited from the PROLIFICA (28) study
at MRC Unit, The Gambia and from the Royal Free Hospital,
London (demographic and clinical parameters in Table 1). The
Gambian cohort was comprised of patients enrolled in the
Prevention of Liver Fibrosis and Cancer in Africa (PROLIFICA)
study. In the Gambian cohort, negative controls were hepatitis
B surface antigen (HBsAg) negative with no liver mass on
ultrasound, inactive CHB patients were HBsAg positive with
HBV viral load <2000 IU/ml and ALT<80 IU/ml, active
CHB patients were HBsAg positive with viral load >2,000 or
ALT>80 IU/ml, CHB cirrhosis patients were HBsAg positive
with a median liver stiffness by Fibroscan (Echosens) >10
kPa or cirrhosis on histology, HCC patients had HCC on
histology or liver mass on ultrasound with alpha-fetoprotein
>400 ng/ml. Patients referred to the liver clinic who had
other tumors on imaging or histology (colorectal metastases,
pancreatic tumor, cholangiocarcinoma, lymphoma, metastatic
melanoma, sarcoma) were used as a comparator group. Serum
was collected for ULBP1 measurement from untreated patients.
Outcome data were collected by the PROLIFICA team and by
the MRC Unit, The Gambia. Tumor volume was estimated by
calculating the volumes of spheroids with dimensions measured
by liver ultrasound scan, using the formula: volume = π∗
( (D1+D2)/2)
3/6.
The UK cohort was derived from patients attending The
Royal Free Hospital liver oncology clinic. Serum was collected
for ULBP1 measurement from patients before any local, systemic
or surgical treatment was received. HCC was defined as patients
meeting radiological criteria for HCC on triple-phase CT or
MRI or with features of HCC on histology following biopsy or
resection. Patients were managed according to EASL-EORTC
clinical practice guidelines 2012 (27). Outcome data were
obtained using NHS Spine. For one experiment ex vivo human
liver and HCC tissue provided by the Tissue Access for Patient
Benefit service at the Royal Free Hospital was used as previously
described (23).
Statistical Analysis
The Mann Whitney-U test was used for comparisons of two
unpaired groups, Spearman rank test was used for correlations
of continuous variables. These tests were performed in GraphPad
Prism version 6. P ≤ 0.05 was considered to be significant
for all tests. Multiple linear regression and Poisson regression
were performed in R (The R Project for Statistical Computing)
version 3.4.2.
RESULTS
Serum concentrations of the NKG2D ligand ULBP1 were
elevated in Gambian patients with HCC compared with either
patients with cirrhosis or with healthy controls (median
ULBP1 concentrations 2626, 691, and 128 pg/ml, respectively,
Figure 1A). A small cohort of individuals with non-HCC
TABLE 1 | Clinical characteristics of the Gambian and UK HCC cohorts and
Gambian control cohort.
Parameter Gambia HCC UK HCC Healthy control
Male:Female
ratio





































Median (range) for age, bilirubin, albumin of the Gambia HCC (n = 43), UK HCC (n = 72),
and Gambia control (n= 23) cohorts, hepatocellular carcinoma (HCC) and healthy control
groups. WHO performance status and AFP are shown for the full UK HCC cohort and
a subset of the Gambia HCC cohort, n shown in table. Student’s t-test with Welch’s
correction was used to calculate p values for continuous variables and Chi square with
Yates’ correction for categorical variables, using the Gambia HCC cohort as a reference.
liver tumors had ULBP1 levels comparable to healthy controls
(median 151 pg/ml) and significantly lower than those with HCC
(Figure 1B). There was no change in the levels of the NKG2D
ligands MICA, MICB, ULBP2, ULBP3 in these same cohorts
(Figure 1C).
To examine whether elevated serum ULBP1 could be derived
from diseased hepatocytes rather than exclusively HCC, we
examined levels in patients with chronic hepatitis B (CHB),
the most important underlying liver disease in The Gambia.
Concentrations were higher in those with active or cirrhotic CHB
than inactive carriers or controls, although remained significantly
lower than in HBV-related HCC (Figure 1D). Serum ULBP1 was
not associated with markers of liver disease including platelet
count, alanine transaminase or serum albumin, or with HBV
viral load (Figures 1E,F), suggesting that in the context of clinical
HCC, ULBP1 production was independent of liver fibrosis,
hepatocyte dysfunction and HBV replication. In 50 patients with
HBV but without HCC treated with tenofovir according to EASL
guidelines, ULBP1 was significantly reduced following 12months
of treatment compared with at treatment initiation (Figure 1G).
To understand whether ULBP1 was released on exosomes
rather than as free protein, size exclusion chromatography was
used to separate patient serum into an exosome-rich fraction
and an exosome-depleted fraction. Imaging cytometry was used
to identify individual exosomes by size and uptake of BODIPY
membrane stain. Representative examples of ULBP1 positive and
negative exosomes are shown in Figure 2A. The exosome-rich
fraction contained many more small, BODIPY-positive events
than the exosome-depleted fraction (39.1 vs. 6.98%) and very few
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FIGURE 1 | Serum ULBP1, but not other NKG2D ligands, is raised in patients with HCC in The Gambia. Serum ULBP1 measured by ELISA in patients with HCC
(n = 43) in the Gambia compared with controls (n = 23) and patients with cirrhosis (n = 60, A) and other liver tumors (n = 8, B). Other NKG2D ligands in the same
cohort (C). Serum ULBP1 in Gambian patients with inactive CHB (n = 34), active CHB (n = 25), or CHB-associated cirrhotic liver disease, HCC and controls (D).
Serum ULBP1 concentrations in individuals with HCC against log10 serum ALT concentration (n = 40), serum albumin (n = 42), and platelet count (n = 43) (E) and
against log10 HBV DNA concentration (n = 40, F). Paired serum ULBP1 in patients with HBV without HCC before and after 12 months of treatment with tenofovir (n =
50, G). Mean and SEM of all groups shown. Levels of significance: *p ≤ 0.05; **p ≤ 0.005; ***p ≤ 0.001; ****p ≤ 0.0001. Mann Whitney-U test was used for
comparisons of two unpaired groups, Spearman rank test was used for correlations of continuous variables, Wilcoxon match-pairs signed rank test was used for
comparisons of paired data.
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FIGURE 2 | Imaging cytometry of serum from Gambian HCC patients with high levels of ULBP1, stained for lipid membrane (BODIPY) and ULBP1. Representative
examples of ULBP1 negative and positive exosomes shown in (A). Serum was separated into exosome and protein fractions by size exclusion column filtration and
imaging cytometry of exosome-rich (B) and exosome depleted (C) fractions was performed. Exosomes gated as small, BODIPY positive events, a proportion of which
(Continued)
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FIGURE 2 | are ULBP1 positive. ULBP1 concentration of whole serum, exosome rich and exosome depleted fractions was assessed by ELISA as in Figure 1 (D, n =
16). Flow cytometry of cell-surface expression of NKG2D on peripheral blood NK cells (E) and CD8 T cells (F) in a subset of Gambian patients with HCC or HBV. Ratio
of NKG2D MFIs on paired peripheral and intrahepatic NK cells stratified by serum ULBP1 (G, n = 7). Cartoon depicting resection of tumour and liver tissue for
short-term culture before ULBP1 ELISA of the conditioned media, ULBP1 concentration by ELISA of conditioned media from paired liver and tumour tissue (n = 1, H).
Mean and SEM of all groups shown. Levels of significance: *p ≤ 0.05; **p ≤ 0.005; ***p ≤ 0.001; ****p ≤ 0.0001. Mann Whitney-U test was used for comparisons of
two unpaired groups.
ULBP1 positive exosomes were seen in the exosome-rich fraction
(Figures 2B,C), suggesting that this was not the major form in
which ULBP1 was present in serum. When split into exosome-
rich and exosome-depleted fractions the ULBP1 concentration
of serum and exosome-depleted fractions was similar, whereas
the ULBP1 concentration of the exosome-rich fraction was
significantly reduced (Figure 2D).
In a subset of Gambian patients with CHB or HCC and where
PBMCs were available, NKG2D expression on peripheral blood
NK cells and T cells was measured by flow cytometry to test
whether it was downregulated by the presence of circulating
NKG2D-ligands. The expression of NKG2D on the surface of
NK and T cells within this patient cohort was not altered in
those patients where ULBP1 was detectable in serum compared
to those with no detectable ULBP1 (Figures 2E,F, gating strategy
shown in Supplementary Figure 1). In seven participants from
the Gambian HCC cohort we were able to compare NKG2D
expression between peripheral and intrahepatic NK cells. There
was no difference in the ratio of peripheral:intrahepatic NKG2D
expression between individuals with ULBP1 above or below 2000
pg/ml (Figure 2G). In one individual from the UK HCC cohort,
small fragments of liver and tumor were weighed and incubated
with a volume of complete RPMI in µl equivalent to 10x the
weight of the tissue in µg. The tissue was incubated for 18 h
at 37◦C, the supernatant was removed and ULBP1 ELISA was
performed. The ULBP1 concentration in the tumor-conditioned
media reached a similar high level to that found in the sera of
HCC patients (5041 pg/ml), whereas the concentration in the
conditioned media from surrounding liver was negligible (202
pg/ml). These data reveal the capacity, at least in this individual,
of HCC (and/or its immune milieu) to shed ULBP1 as a putative
immune evasion strategy.
We next sought to examine whether ULBP1 levels in serum
could predict outcome in HCC. In a subset of Gambian patients
where retrospective follow-up data was available, there was
significantly shorter survival in HCC patients with serum ULBP1
>2000 pg/ml at the time of presentation (median survival 26
vs. 74 days, p = 0.0029, hazard ratio (HR) 2.37, Figure 3A).
Median survival for the whole cohort was 33 days from blood
sampling to death. This was not simply a reflection of high serum
levels of ULBP1 reflecting larger tumors since ULPB1 levels did
not correlate with HCC volume estimated by ultrasound scan
(Figure 3B).
Using a second, larger (n = 72) cohort of HCC patients we
sought to validate the use of ULPB1 as a prognostic marker
for HCC. In this UK-based cohort with HCC arising on a
background of a range of underlying liver pathologies we were
also able to examine whether elevation of ULBP1 was restricted
to HBV-related HCC. We found that ULPB1 was similarly
elevated in HCC resulting from HBV, HCV or other etiologies
(median 907, 636, 301 pg/ml for HBV/HCV/other causes,
respectively, differences not significant, Figure 3C). There was no
association between serum ULBP1 and AFP (alpha fetoprotein),
suggesting that ULBP1 secretion is mechanistically distinct
from AFP production (Figure 3D). Importantly there was no
significant difference in ULBP1 concentration between resected
and unresected tumors at a population level (Figure 3E), and no
significant difference in proportions with ULBP1 concentrations
>2000 pg/ml (11/61 vs. 0/10, p = 0.34 by Fisher’s exact test).
As expected, tumor resection was associated with a significant
improvement in survival compared with unresected HCC (HR
0.16, p = 0.0003, Figure 3F). In a retrospective analysis of
outcomes, serum ULBP1 concentration >2000 pg/ml was again
significantly associated with a poorer prognosis (median survival
267 vs. 462 days, p= 0.024, HR 2.1, Figure 3G). Median survival
for the whole cohort was 427 days from blood sampling to death.
When divided into early (Barcelona Clinic Liver Cancer
(BCLC) 0/A, Figure 3H) and late (BCLC B/C/D, Figure 3I) stage
disease, survival differences according to ULPB1 levels in both
groups showed raised hazard ratios for death, suggesting ULBP1
may be prognostic in both early and late disease, although p
values were non-significant owing to a lack of statistical power
(median survival 1077 vs. 535 days, p = 0.15, HR = 2.9 in
early stage, 399 vs. 198 days, p = 0.096, HR = 1.8 in late
stage). In univariable analysis, ULBP1 had a HR for death of
2.59 (p = 0.004, Table 2). Raised AFP was not significantly
associated with worse prognosis, in keeping with previous work
showing very limited prognostic effect even in large cohorts
(29). BCLC and CLIP (Cancer of the Liver Italian Program
(30)) scores were predictive of outcome, WHO performance
status did not reach significance (p = 0.063). Importantly, in
multivariate analysis including BCLC stage (which is used to
guide clinical management (27)), age and sex, ULBP1 was an
independent predictor of survival (hazard ratio 2.11, 95% CI
1.02-4.02, Table 3). Similar data incorporating CLIP score is
shown in Supplementary Table 1.
DISCUSSION
Shed NKG2D ligands have been shown to impair NK and T
cell function in vitro (9, 31) and to mediate tumor evasion
in animal models (32, 33), although in some settings soluble
NKG2D ligands may paradoxically mediate tumor rejection
(13). In studies of HCC, soluble MICA expression has been
associated with poor prognosis (34); conversely, expression
of ULBP1 on the tumor surface has been associated with
improved survival (26). We did not demonstrate elevation
of MICA in patients from The Gambia, but found elevated
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FIGURE 3 | ULBP1 predicts outcome in HCC patients from the The Gambia and The UK. Kaplan-Meier curve comparing survival from the day of baseline clinical
assessment between groups with serum ULBP1 above and below 2000 pg/ml in The Gambia (n = 37, A). Serum ULBP1 concentrations in individuals with HCC
against estimated tumor volume (n = 27, B). Serum ULBP1 concentration in HBV-associated HCC (n = 8), HCV-associated HCC (n = 18) and HCC of other causes
(n = 45), from a UK cohort (C). Serum ULBP1 concentration in UK patients against alpha fetoprotein (AFP, D). Serum ULBP1 concentration (E) and Kaplan-Meier
curve of survival (F) in HCC patients that went on to resection (n = 10) and those whose tumors were not resected (n = 61). Kaplan-Meier curve comparing survival
from the day of baseline clinical assessment between groups with serum ULBP1 above and below 2000 pg/ml in the UK whole cohort (n = 72, G). Kaplan-Meier
curves comparing survival between groups with serum ULBP1 above and below 2000 pg/ml in UK patients with early stage (BCLC stage 0/A, n = 18, H) and late
stage (BCLC B-D, n = 54, I) HCC. Mean and SEM of all groups shown. Levels of significance: *p ≤ 0.05; **p ≤ 0.005; ***p ≤ 0.001; ****p ≤ 0.0001. Mann Whitney-U
test was used for comparisons of two unpaired groups, Spearman rank test was used for correlations of continuous variables. For Kaplan-Meier curves, p-values for
difference in survival and hazard ratios were calculated by log-rank test.
serum ULBP1, suggesting the loss of cell surface ULBP1 seen
in other studies may be due to shedding of this ligand by
HCC into the circulation. Immunohistochemical staining of
tumor tissue for ULBP1 combined with serum measurement
of ULBP1 may be able to demonstrate a correlation between
ULBP1 loss at the cell surface and ULBP1 presence in serum.
In addition it will be revealing to understand whether other
histological features of the tumor including histological subtype,
vascularity and immune infiltration are associated with ULBP1
secretion as these may provide insights into the mechanism
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of ULBP1 production and shedding. Elevated MICA levels in
HCC have been shown to be highly correlated with vascular
invasion (34). As ULBP1 was not predominantly present on
membrane-bound vesicles, shedding may occur by the action
of a protease as previously described for other NKG2D ligands
(35), although in some in-vitro systems ULBP1 is shed only at
low levels (12). NKG2D ligands are known to be differentially
expressed in a variety of malignant settings and to behave non-
redundantly (36), which may explain why the other NKG2D
ligands were not elevated. NKG2D was not downregulated on
peripheral NK or CD8T cells in the context of detectable
ULBP1, but may have been affected within the tumor micro-
environment, where NKG2D is known to be significantly
TABLE 2 | Univariable analysis of risk factors for mortality in UK HCC cohort.
Variable Unadjusted HR 95% CI p-value
Age (continuous variable) 1 0.98–1.03 0.49
Male 1.96 0.95–4.73 0.09
ULBP1 > 2000 pg/ml 2.59 1.28–4.80 0.004
AFP 20-200 1.34 0.73–2.41
AFP >200 1.89 0.96–3.56 0.1692
BCLC 0 1 –
BCLC A 1.48 0.38–9.68
BCLC B 4.64 1.31–29.47
BCLC C 3.89 1.17–24.12
BCLC D 3.13 0.68–21.88 0.009
WHO Performance 1 1 –
WHO Performance 1 1.46 0.84–2.52
WHO Performance 2 6.73 1.61–19.06
WHO Performance 3 1.1 0.32–2.80 0.063
CLIP 0 1 –
CLIP 1 2.09 1.08–4.11
CLIP 2 3.61 1.77–7.34
CLIP 3 8.99 3.22–21.85
CLIP 4 21.39 3.38–75.16 0.006
Hazard rate ratio for death and p value calculated by linear regression for ULBP1, AFP as
a categorical variable, and three clinical scoring systems BCLC stage, WHO performance
status and CLIP score. For AFP, BCLC, WHO performance and CLIP p values for trend
are shown.
downregulated (23). Future work should combine measurement
of serum ULBP1 with phenotypic and functional assessment of
tumor-infiltrating NK cells.
We have demonstrated that soluble ULBP1 is secreted in
the context of HCC, but not metastases of other tumors to
the liver, revealing a degree of diagnostic specificity. Although
serum ULBP1 was significantly higher in patients with HCC,
the fact that is was also detectable to a variable degree in
HBV-related disease without HCC makes it less appealing as
an HCC screening tool. Instead, our data show that ULBP1
elevated above 2000 pg/ml is a predictor of poor prognosis in
HCC, pointing to the need to explore its utility as a prognostic
biomarker in larger studies. Although our test and validation
cohorts were small, ULBP1 showed consistent predictive capacity
in patients from the UK and the Gambia, despite differences
in etiology and overall survival between cohorts, and the
management options available. The observation that serum
ULBP1 falls in patients with active HBV following one year
of HBV treatment with the nucleotide reverse-transcriptase
inhibitor tenofovir, coupled with the numerically greater (but
not statistically significant) ULBP1 in HBV-associated HCC
than in HCC without HBV or HCV suggests a direct effect
of HBV on ULBP1 production. The mechanism of this is
yet to be elucidated, it may be caused by DNA damage or
clonal expansion of hepatocytes (37), or another action of
HBV. Treatment of HBV with tenofovir is known to reduce
the incidence of HCC (38, 39). This raises the question of
whether ULBP1 could predict progression to HCC. Whether
ULBP1 can predict progression to HCC and the possibility
of incorporating this marker into HCC screening should
be examined in a large, prospectively followed and well
characterized clinical cohort.
The UK HCC cohort was older, had less severe liver
disease, less HBV and more HCV compared with the Gambian
HCC patients. In the Gambia diagnosis was by ultrasound
and AFP with histopathology in some cases and no specific
management was available, whereas patients in the UK cohort
were diagnosed using triple phase CT supported by MRI
and histopathology where appropriate and managed with liver
resection, liver transplant, trans-arterial chemo-embolisation and
systemic chemotherapy according to EASL-EORTC guidelines
(27). Triple-phase CT and MRI imaging were unavailable in
TABLE 3 | Multivariate analysis of risk factors for mortality in UK HCC cohort using age, sex, and BCLC group.
Variable Unadjusted HR 95% CI p-value Adjusted HR 95% CI p-value
Age (continuous variable) 1 0.98–1.03 0.49 0.99 0.97–1.03 0.99
Male 1.96 0.95–4.73 0.09 1.31 0.61–3.26 0.52
ULBP1 > 2000 pg/ml 2.59 1.28–4.80 0.004 2.11 1.02–4.02 0.03
BCLC A 1.48 0.38–9.68 0.62 1.38 0.35–9.12 0.68
BCLC B 4.64 1.31–29.47 0.04 3.61 0.95–23.71 0.1
BCLC C 3.89 1.17–24.12 0.06 3.44 1.00–21.65 0.1
BCLC D 3.13 0.68–21.88 0.17 2.81 0.59–20.09 0.22
Age, sex, BCLC group, and serum ULBP1 >2000 pg/ml as a categorical variable were included in a Poisson regression model to calculate multivariate hazard rate ratios for death and
associated p values.
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both the study and the local health service in The Gambia and
it would have been unethical to try to provide this given the
absence of treatment options. We expect that in an endemic area
our diagnostic strategy would have led to more under-diagnosis
(and exclusion from the study) than over-diagnosis. The two
settings are complementary—one reflects the resource-limited
setting where the majority of HCC occurs and where a serum-
based test might contribute greatly to the available diagnostic
tools, the other provides a high level of clinical characterization
to validate the findings and represents the sort of cohort in
which novel immunotherapy could be trialed. It is interesting
that the hazard ratios for death were of a similar magnitude in
the two cohorts despite the large difference in survival. Median
survival in the Gambian cohort was 33 days compared with 427
days in the UK cohort, hazard ratios for death associated with a
ULBP1 > 2000 pg/ml were 2.4 and 2.1, respectively. The study
was not designed to examine the reasons for this difference,
which is likely multifactorial. It may combine late diagnosis in
The Gambia compared with the UK where at-risk patients are
screened regularly, improved survival following diagnosis due to
treatment or other factors, or differences in the pathology in the
different settings. This is supported by the difference in WHO
performance status at enrolment between the UK and Gambian
HCC cohorts (0.69 vs. 1.958, p = 0.0002, Table 1). However
the consistency of our findings suggests ULBP1 is prognostic
in a variety of settings and implies that the effect of ULBP1
may be similar in early and late stage HCC. Elevated ULBP1
predicted poor outcome even after accounting for BCLC stage
and was unrelated to AFP, suggesting that ULBP1 may capture
additional information about tumor biology distinct from that of
existing clinical and biochemical markers and supports the idea
that NKG2D ligand secretion can promote tumor progression
in vivo.
Further work is required to confirm the findings in a
large, prospective cohort, where appropriate clinical cut-offs
for ULBP1 can be explored. Follow-up of the existing HBV
cohort will allow us to assess whether elevated ULBP1 levels
may predict the development (as well as the outcome) of
malignancy in the setting of HBV-related liver disease. Future
studies, possibly using humanized mouse models, are required
to explore whether the ULBP1/NKG2D system could be a novel
therapeutic target in HCC. In a recent study using a murine
model, antibodies blocking MICA secretion by tumors while
simultaneously activating NK cells were shown to be therapeutic
in a model of melanoma (18). Our data support the design and
evaluation of a similar antibody to bind ULBP1 in human HCC.
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